MedTrace Logo

MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

NCT06980519 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-05-22

No results posted yet for this study

Summary

The purpose of this Expanded Access Program (EAP) is to allow use of the investigational therapeutic agent, MNPR-101-PCTA-177Lu, for treatment of urokinase plasminogen activator receptor (uPAR)-positive solid tumors identified via positron emission tomography / computed tomography (PET/CT) with investigational imaging agent MNPR-101-DFO\*-89Zr.

Conditions

  • Cancer
  • Solid Tumor
  • Solid Tumor Cancer
  • Oncology
  • uPAR-positive Solid Tumor
  • Urokinase Plasminogen Activator Receptor-positive Solid Tumor

Interventions

BIOLOGICAL

MNPR-101-PCTA-177Lu

MNPR-101-PCTA-177Lu is a monoclonal antibody-radionuclide conjugate intended to target and deliver radioactivity to solid tumors expressing uPAR.

Sponsors & Collaborators

  • Monopar Therapeutics

    lead INDUSTRY

Principal Investigators

  • Ebrahim S. Delpassand, M.D. Chairman & Medical Director, Nuclear Medicine · Excel Diagnostics & Nuclear Oncology Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06980519 on ClinicalTrials.gov